Coronary Bifurcation Stenting (COBIS) Registry in South Korea

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hyeon-Cheol Gwon, Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT00851526
First received: February 25, 2009
Last updated: July 15, 2012
Last verified: July 2012

February 25, 2009
July 15, 2012
January 2004
December 2008   (final data collection date for primary outcome measure)
Incidence of the composite outcome of all-cause death, MI, or any PCI/CABG [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00851526 on ClinicalTrials.gov Archive Site
Incidence of stent thrombosis, and periprocedural MI [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Coronary Bifurcation Stenting (COBIS) Registry in South Korea
Coronary Bifurcation Stenting (COBIS) Registry in South Korea

The COBIS registry is multi-center, real-world registry of drug-eluting stenting in coronary bifurcation lesions in South Korea.

The aim of the study was to find out the current status of bifurcation drug-eluting stenting and determine the prognostic factors for long-term outcome in South Korea.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Patients with coronary bifurcation lesion treated with drug-eluting stents

Coronary Bifurcation Lesion
Not Provided
Coronary bifurcation lesion

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1919
December 2008
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age >= 18 years
  • Any type of de novo bifurcation lesion with a parent vessel >= 2.5 mm and side branch>= 2.0 mm by visual estimation
  • Treated with drug-eluting stent

Exclusion Criteria:

  • Cardiogenic Shock
  • ST elevation MI within 48hours
  • Expected survival less than 1 year
  • Left main bifurcation
  • Allergy to the antiplatelets
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT00851526
2007-04-042
Not Provided
Hyeon-Cheol Gwon, Samsung Medical Center
Samsung Medical Center
Not Provided
Not Provided
Samsung Medical Center
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP